CA2389117A1 - Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes - Google Patents
Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes Download PDFInfo
- Publication number
- CA2389117A1 CA2389117A1 CA002389117A CA2389117A CA2389117A1 CA 2389117 A1 CA2389117 A1 CA 2389117A1 CA 002389117 A CA002389117 A CA 002389117A CA 2389117 A CA2389117 A CA 2389117A CA 2389117 A1 CA2389117 A1 CA 2389117A1
- Authority
- CA
- Canada
- Prior art keywords
- mitochondria
- replicative
- oocytes
- donor cell
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000287 oocyte Anatomy 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 105
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 198
- 230000003362 replicative effect Effects 0.000 claims abstract description 77
- 238000012546 transfer Methods 0.000 claims abstract description 55
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 36
- 238000000338 in vitro Methods 0.000 claims abstract description 26
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 230000037041 intracellular level Effects 0.000 claims abstract description 16
- 230000004720 fertilization Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 86
- 241000894007 species Species 0.000 claims description 31
- 210000002257 embryonic structure Anatomy 0.000 claims description 28
- 210000003855 cell nucleus Anatomy 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 23
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 15
- 210000004940 nucleus Anatomy 0.000 claims description 15
- 230000013020 embryo development Effects 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000001850 reproductive effect Effects 0.000 claims description 9
- 230000009946 DNA mutation Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 210000003754 fetus Anatomy 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 230000007159 enucleation Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000000520 microinjection Methods 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 210000001109 blastomere Anatomy 0.000 claims description 4
- 230000001627 detrimental effect Effects 0.000 claims description 4
- 230000031864 metaphase Effects 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 210000003981 ectoderm Anatomy 0.000 claims description 2
- 210000001900 endoderm Anatomy 0.000 claims description 2
- 210000001339 epidermal cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 210000003716 mesoderm Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 210000002459 blastocyst Anatomy 0.000 description 16
- 238000013467 fragmentation Methods 0.000 description 16
- 238000006062 fragmentation reaction Methods 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000030833 cell death Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 7
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 231100000182 Sperm DNA damage Toxicity 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- 230000006721 cell death pathway Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940012982 picot Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 230000000270 postfertilization Effects 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- -1 FSH Chemical compound 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 208000009564 MELAS Syndrome Diseases 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001665167 Solter Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000034790 Twin pregnancy Diseases 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101100082060 Xenopus laevis pou5f1.1 gene Proteins 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 239000008150 cryoprotective solution Substances 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003772 granulosa lutein cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions et des procédés améliorant le potentiel de développement d'oocytes ou de zygotes par augmentation des niveaux intracellulaires de mitochondries réplicatives dans les oocytes ou les zygotes. Selon un aspect de l'invention, les niveaux intracellulaires de mitochondries réplicatives sont augmentés par introduction de mitochondries réplicatives dans les oocytes ou les zygotes. Les oocytes peuvent être fécondés afin d'obtenir un zygote à niveaux intracellulaires augmentés de mitochondries réplicatives. On peut utiliser les procédés et compositions selon l'invention pour améliorer les procédés de fécondation in vitro et de transfert d'embryon, ainsi que les techniques de transfert de matériel nucléaire.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16179799P | 1999-10-27 | 1999-10-27 | |
| US60/161,797 | 1999-10-27 | ||
| PCT/CA2000/001283 WO2001030980A2 (fr) | 1999-10-27 | 2000-10-27 | Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2389117A1 true CA2389117A1 (fr) | 2001-05-03 |
Family
ID=22582774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002389117A Abandoned CA2389117A1 (fr) | 1999-10-27 | 2000-10-27 | Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1234021A2 (fr) |
| JP (1) | JP2003512833A (fr) |
| AU (1) | AU1123301A (fr) |
| CA (1) | CA2389117A1 (fr) |
| WO (1) | WO2001030980A2 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1442115B9 (fr) | 2001-11-15 | 2009-12-16 | Children's Medical Center Corporation | Techniques d'isolation, de developpement et de differenciation de cellules souches provenant de villosites choriales, de liquide amniotique ainsi que de placenta et applications therapeutiques |
| GB0200804D0 (en) | 2002-01-14 | 2002-03-06 | Univ Birmingham | Cloning methods and other methods of producing cells |
| US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
| CA2897658A1 (fr) | 2004-05-17 | 2005-12-22 | The General Hospital Corporation | Compositions comprenant des cellules souches germinales femelles et leurs procedes d'utilisation |
| EP2697365A4 (fr) * | 2011-04-14 | 2014-07-23 | Gen Hospital Corp | Compositions et méthodes de transfert d'énergie autologue des mitochondries dans les cellules germinales |
| AU2014202447B2 (en) * | 2011-04-14 | 2015-05-07 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
| EA201490050A1 (ru) | 2011-06-29 | 2014-07-30 | Зе Дженерэл Хоспитэл Корпорейшн | Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток |
| WO2019113743A1 (fr) * | 2017-12-11 | 2019-06-20 | 清华大学 | Procédé de modification génétique |
| CN114214270B (zh) * | 2021-12-17 | 2023-11-24 | 中国农业科学院北京畜牧兽医研究所 | 一种调控冷冻牛卵母细胞的发育能力的方法及其应用 |
-
2000
- 2000-10-27 JP JP2001533963A patent/JP2003512833A/ja active Pending
- 2000-10-27 CA CA002389117A patent/CA2389117A1/fr not_active Abandoned
- 2000-10-27 AU AU11233/01A patent/AU1123301A/en not_active Abandoned
- 2000-10-27 WO PCT/CA2000/001283 patent/WO2001030980A2/fr not_active Application Discontinuation
- 2000-10-27 EP EP00972510A patent/EP1234021A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1234021A2 (fr) | 2002-08-28 |
| WO2001030980A2 (fr) | 2001-05-03 |
| WO2001030980A3 (fr) | 2001-11-29 |
| AU1123301A (en) | 2001-05-08 |
| JP2003512833A (ja) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Galli et al. | Mammalian leukocytes contain all the genetic information necessary for the development of a new individual | |
| Wallach et al. | Micromanipulation: its relevance to human in vitro fertilization | |
| CA2317494A1 (fr) | Clonage faisant appel a des noyaux donnes de cellules foetales et adultes differenciees | |
| Lacham-Kaplan et al. | Fertilization of mouse oocytes using somatic cells as male germ cells | |
| US20080044392A1 (en) | Isolation of Stem Cell-Like Cells and Use Thereof | |
| CA2389117A1 (fr) | Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes | |
| JP2010520751A (ja) | 乾癬のブタモデル | |
| Rhind et al. | 69 Dolly: a final report | |
| Arat et al. | 25 COLD STORAGE OF TISSUES AS SOURCE FOR DONOR CELLS DOES NOT REDUCE THE IN VITRO DEVELOPMENT OF BOVINE EMBRYOS FOLLOWING NUCLEAR TRANSFER | |
| Vajta et al. | 75 HIGHLY EFFICIENT AND RELIABLE CHEMICALLY ASSISTED ENUCLEATION METHOD FOR HANDMADE CLONING IN CATTLE AND SWINE | |
| Matshikiza et al. | 57 EMBRYO DEVELOPMENT FOLLOWING INTERSPECIES NUCLEAR TRANSFER OF AFRICAN BUFFALO (SYNCERUS CAFFER), BONTEBOK (DAMALISCUS DORCUS DORCUS) AND ELAND (TAUROTRAGUS ORYX) SOMATIC CELLS INTO BOVINE CYTOPLASTS | |
| Bartels et al. | 27 Birth of Africa’s first nuclear-transferred animal produced with handmade cloning | |
| Begin et al. | 28 PREGNANCIES RESULTED FROM GOAT NT EMBRYOS PRODUCED BY FUSING COUPLETS IN THE PRESENCE OF LECTIN | |
| Wani et al. | 78 CHRONOLOGICAL EVENTS OF IN VITRO MATURATION IN CAMEL (CAMELUSDROMEDARIES) OOCYTES | |
| Kim et al. | 47 BOVINE OOCYTE CYTOPLASM SUPPORTS NUCLEAR REMODELING BUT NOT REPROGRAMMING OF MURINE FIBROBLASTS | |
| DeLegge et al. | 34 Effect of genotype and cell line on the efficiency of live calf production by somatic cell nuclear transfer | |
| Behboodi et al. | 29 HEALTH AND REPRODUCTIVE PROFILES OF NUCLEAR TRANSFER GOATS PRODUCING THE MSP1-42 MALARIA ANTIGEN | |
| Nel-Themaat et al. | 61 ISOLATION AND CULTURE OF SOMATIC CELLS OBTAINED FROM SEMEN AND MILK OF GULF COAST NATIVE SHEEP | |
| BLASTOCYSTS | 238 Theriogeno [ogy | |
| Nel-Themaat | Gamete and cell technologies for use in biological resource banking | |
| Rho et al. | 70 PRODUCTION OF CLONES BY FIBROBLAST NUCLEAR TRANSFER FROMAN X-AUTOSOME TRANSLOCATION CARRIER COW | |
| Landry | Reconstruction of nuclear transfer embryos in goats and cattle [electronic resource] | |
| Kim et al. | 48 EFFECT OF INSULIN-LIKE GROWTH FACTOR-1 SUPPLEMENT TO NCSU-23 MEDIUM ON PREIMPLANTATION DEVELOPMENT OF PORCINE EMBRYOS DERIVED FROM IN VITRO FERTILIZATION AND SOMATIC CELL NUCLEAR TRANSFER | |
| Hoffert et al. | 42 ANGIOGENESIS IN CLONED AND IVF-DERIVED BOVINE PREGNANCIES AT DAY 30 OF GESTATION | |
| Baqir et al. | 26 ABERRANT REPROGRAMMING OF IMPRINTED GENE EXPRESSION IN ENLARGED PLACENTAS OF MICE CLONED FROM ES CELLS TREATED WITH TSA OR 5AZAC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |